pembrolizumab + enzalutamide + androgen deprivation therapy

A combination regimen of **pembrolizumab** (a monoclonal antibody that inhibits the programmed cell death protein 1, PD-1), **enzalutamide** (a small molecule androgen receptor inhibitor), and **androgen deprivation therapy** (ADT; hormonal therapy aimed at reducing androgen levels, typically via GnRH agonists or antagonists or orchiectomy) used primarily for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Pembrolizumab is an immune checkpoint inhibitor that enhances antitumor immune responses by blocking the PD-1 pathway. Enzalutamide blocks androgen receptor activity, thereby inhibiting androgen-driven tumor cell proliferation. ADT further reduces androgen levels systemically, depriving prostate cancer cells of growth signals. The combination has been investigated in multiple clinical trials for potential additive or synergistic effects, though results to date indicate only limited additional clinical benefit over existing standards of care in mCRPC, with increased toxicity reported[1][2][4][5].

Brand names

KeytrudaXtandi

Other names

PD-1 inhibitor + androgen receptor inhibitor + ADTpembrolizumab + enzalutamide + ADT